RETATRUTIDE 20MG

RETATRUTIDE 20MG | TRIPLE HORMONE RECEPTOR AGONIST

Retatrutide (LY3437943) represents the cutting edge of metabolic research. As a "tri-agonist," it targets three essential nutrient-stimulating hormone receptors: GLP-1 (Glucagon-like peptide-1), GIP (Glucose-dependent insulinotropic polypeptide), and GCGR (Glucagon receptor). This 20mg high-concentration formulation is engineered for intensive research into advanced weight regulation and glycemic control.

Key Research Mechanisms

• Triple Receptor Synergy: Unlike previous generations of dual agonists, Retatrutide’s triple action is researched for its ability to maximize calorie expenditure and appetite suppression simultaneously.

• Glucagon Receptor Activation: The inclusion of Glucagon receptor targeting is a focal point for studies involving increased basal metabolic rate and enhanced adipose tissue breakdown (lipolysis).

• Incretin Mimicry: Research explores how the GIP and GLP-1 components work together to optimize insulin secretion and improve glucose tolerance more effectively than single-target compounds.

• Liver Health Research: Recent studies utilize Retatrutide to investigate the reduction of hepatic fat content and its potential implications for non-alcoholic fatty liver disease (NAFLD) models.

Product Specifications

• Concentration: 20mg

• Form: Lyophilized Powder

• Purity: >99% (HPLC Verified)

• Molecular Formula: $C_{221}H_{342}N_{56}O_{68}$

• Storage: Store at -20°C for long-term stability. Protect from moisture and light exposure to prevent peptide degradation.

The LNGVIX Advantage

Our Retatrutide is synthesized to the highest pharmaceutical-grade standards, ensuring consistent bioavailability and sequence fidelity for high-stakes research environments.

LABORATORY PRECAUTION: This product is intended for laboratory research use only. It is not for human consumption, diagnostic, or therapeutic use. Handle with extreme caution in a controlled research setting.